Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brendan Connell

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Cardiovascular Drugs and Therapy|November 11, 2024
Associations of SGLT2i with Cardiorenal Outcomes Among Diabetics with Prostate Cancer on Hormone TherapyEfstratios Koutroumpakis, Rushin Patel, Sumanth Khadke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jawNoopur Raje, Sook-Bin Woo, Karen Hande, et al.
Cancer Discovery|January 8, 2026
Acquired on-target alterations drive clinical resistance to p53-Y220C reactivatorsFerran Fece de la Cruz, Andreas Varkaris, Parasvi S Patel, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Cardiovascular Drugs and Therapy|November 11, 2024
Associations of SGLT2i with Cardiorenal Outcomes Among Diabetics with Prostate Cancer on Hormone TherapyEfstratios Koutroumpakis, Rushin Patel, Sumanth Khadke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jawNoopur Raje, Sook-Bin Woo, Karen Hande, et al.
Cancer Discovery|January 8, 2026
Acquired on-target alterations drive clinical resistance to p53-Y220C reactivatorsFerran Fece de la Cruz, Andreas Varkaris, Parasvi S Patel, et al.
Pageof 2